Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.
Che-Kai Tsao, MD
Advertisement
Articles by Che-Kai Tsao, MD
Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.
Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.
Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.
Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.
Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Tsao on Improving Outcomes in RCCMay 15th 2020
Dr. Tsao on Rationale for Staging Renal Cell CarcinomaMarch 9th 2020
- Dr. Tsao on Improving Outcomes in RCC
May 15th 2020
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5